A Comprehensive Assessment of Onco-Panel Sequencing across Multiple Laboratories and Technologies

FDA-led Sequencing Quality Control Phase 2 (SEQC2) Consortium

Onco-panel sequencing targets a very small portion of the genome and thus enables a detection of rare but clinically relevant mutations. Accurate diagnosis and subsequent therapy selection and tailoring depend on thorough and accurate characterization of tumor mutations. The lack of tumor reference samples, efficient panel validation processes, and standard practice guidelines is hindering the development of onco-panel sequencing and the realization of its benefits in cancer diagnosis and treatment.

Download this poster, presented at AMP 2019, to explore the methods, results, and conclusions of this study.

Complete the form below to access this scientific poster